AI
Tuesday, April 03, 2018 8:18:19 AM
BPTH - 1.77 Pre-market now at 2.97/2.99
Bio-Path Reports Anti-Leukemia Drug In Phase 2 is Safe, Helps 50% Of Patients; Shares Rise Pre-Bell
Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML)
Bio-Path Reports Anti-Leukemia Drug In Phase 2 is Safe, Helps 50% Of Patients; Shares Rise Pre-Bell
Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML)
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
